Outcome	Vaccine	No. trials	No. participants	RR (95% CI)	NNT (95% CI)	Analysis
Rotavirus diarrhoea: episodes	Rhesus tetravalent (RRV‐TV)	11	11,590	0.58 (0.47 to 0.72)	19 (15 to 25)	Analysis 10.1
	Rhesus monovalent (RRV, RRV‐D, RRV‐DS1, or RRV‐ST3)	9	1715	0.60 (0.46 to 0.78)	13 (9 to 22)	Analysis 10.1
	Bovine (RIT‐4237)	10	3663	0.65 (0.48 to 0.86)	—	Analysis 10.1
	Bovine (WC3)	3	782	0.77 (0.46 to 1.28)	—	Analysis 10.1
	Bovine‐human (W179‐9)	3	433	0.33 (0.19 to 0.56)	7 (5 to 12)	Analysis 10.1
	Bovine‐human (WC3‐QV)	1	405	0.33 (0.19 to 0.58)	7 (5 to 13)	Analysis 10.1
	Human (89‐12)	2	2201	0.32 (0.23 to 0.45)	11 (8 to 15)	Analysis 10.1
	Human (M37)	1	281	1.01 (0.45 to 2.25)	—	Analysis 10.1
Rotavirus diarrhoea: severe episodes	Rhesus tetravalent (RRV‐TV)	7	9569	0.40 (0.28 to 0.57)	18 (15 to 22)	Analysis 10.2
	Rhesus monovalent (RRV‐MMU 18006)	4	1037	0.52 (0.27 to 0.97)	23 (13 to 72)	Analysis 10.2
	Bovine (RIT‐4237)	5	2131	0.38 (0.19 to 0.79)	24 (16 to 53)	Analysis 10.2
	Bovine (WC3)	3	782	0.57 (0.29 to 1.12)	14 (8 to 37)	Analysis 10.2
	Bovine‐human (W179‐9)	1	325	0.14 (0.05 to 0.42)	—	Analysis 10.2
	Bovine‐human (QHBRV)	1	405	0.31 (0.16 to 0.62)	—	Analysis 10.2
	Human (89‐12)	2	2201	0.21 (0.13 to 0.35)	14 (10 to 20)	Analysis 10.2
All‐cause diarrhoea: episodes	Rhesus tetravalent (RRV‐TV)	5	6561	0.89 (0.84 to 0.93)	12 (10 to 17)	Analysis 10.3
	Rhesus monovalent (RRV or RRV‐D or RRV‐DS1 or RRV‐ST3)	6	1145	0.82 (0.69 to 0.98)	8 (5 to 13)	Analysis 10.3
	Bovine (RIT‐4237)	7	2772	0.82 (0.67 to 1.01)	16 (10 to 35)	Analysis 10.3
	Bovine (WC3)	1	104	0.48 (0.28 to 84)	—	Analysis 10.3
	Bovine‐human (W179‐9)	3	433	0.60 (0.50 to 0.72)	4 (3 to 7)	Analysis 10.3
	Human (M37)	1	281	0.91 (0.57 to 1.44)	—	Analysis 10.3